ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: () Report Updated: Oct 27, 2014 | Print This Page

Get more stock ratings by Louis Navellier

(PATH)

Rating: Volatility:
Total Grade: Industry:
Competitors:

Stock Analysis

Rating: Monthly View

A
B
C
D
F
November December January February March April May June July August September October

Rating: Weekly View

This Week: down no change
Last Week: same no change
Two Weeks Ago: up no change
service keys

© quotemedia

Company Profile

NuPathe Inc., a biopharmaceutical company, focuses on the development and commercialization of branded therapeutics for neurological and psychiatric disorders. The companyís lead product candidate is NP101, an active, single-use, transdermal sumatriptan patch for the treatment of migraine. Its product candidates in preclinical development stage comprise NP201 for the continuous symptomatic treatment of Parkinsonís disease; and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The company develops its products using SmartRelief, a proprietary transdermal medication delivery technology based on iontophoresis, a non-invasive method of actively transporting molecules, such as sumatriptan; and Long-Acting Delivery, a biodegradable implant technology that allows delivery of therapeutic levels of medication over a period of months with a single dose. The company was founded in 2005 and is headquartered in Conshohocken, Pennsylvania.

Recent News: